Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Institutional & Insider Ownership
0.1% of Nihon Kohden shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Nihon Kohden and Beta Bionics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nihon Kohden | $1.56 billion | 1.07 | $95.79 million | $0.55 | 18.02 |
| Beta Bionics | $100.25 million | 8.51 | -$73.20 million | ($1.65) | -11.49 |
Nihon Kohden has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Nihon Kohden and Beta Bionics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nihon Kohden | 0 | 2 | 0 | 0 | 2.00 |
| Beta Bionics | 1 | 4 | 8 | 0 | 2.54 |
Beta Bionics has a consensus target price of $22.91, indicating a potential upside of 20.83%. Given Beta Bionics’ stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than Nihon Kohden.
Profitability
This table compares Nihon Kohden and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nihon Kohden | 5.90% | 9.17% | 6.47% |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
Risk & Volatility
Nihon Kohden has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.39, indicating that its share price is 239% more volatile than the S&P 500.
Summary
Nihon Kohden beats Beta Bionics on 8 of the 14 factors compared between the two stocks.
About Nihon Kohden
Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Nihon Kohden Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nihon Kohden and related companies with MarketBeat.com's FREE daily email newsletter.
